Poolbeg Pharma PLC Ordinary Shares (POLB)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
7.70p
Buy
8.00p
0.20p (+2.38%)
Prices updated at 05 Jun 2026, 17:31 BST
| Prices minimum 15 mins delay
Prices in GBX
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralise ...
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| - | - | |
| - | - | |
| -6m | -6m | |
| - | - | |
| -6m | -6m | |
| -6m | -6m | |
| Sales, General and administrative | 5m | 5m |
| Interest expenses | - | - |
| Provision for income taxes | -154,000 | -79,000 |
| Operating expenses | 6m | 6m |
| Income before taxes | -6m | -6m |
| Net income available to common shareholders | -6m | -6m |
| -0.0116 | -0.0094 | |
| Net interest income | 428,000 | 253,000 |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -0.0116 | -0.0094 |
| Free cash flow per share | -0.0091 | -0.0097 |
| Book value/share | 0.0249 | 0.0171 |
| Debt equity ratio | - | - |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 9m | 8m |
| Current liabilities | 974,000 | 1m |
| Total capital | 9m | 9m |
| Total debt | - | - |
| Total equity | 9m | 9m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 10m | 10m |
| Total liabilities | - | - |
| Cash and cash equivalents | 8m | 8m |
| Common stock | 500m | 697m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 12m | 8m |
| Cash dividends paid | - | - |
| -5m | -5m | |
| Investments (gains) losses | 299,000 | 173,000 |
| 8m | 8m | |
| Net income | - | - |
| -5m | -5m | |
| -129,000 | -80,000 |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
